Sana Biotechnology (NASDAQ:SANA) Posts Earnings Results, Beats Estimates By $0.01 EPS

Sana Biotechnology (NASDAQ:SANA) posted its earnings results on Thursday. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.01, FiscalAI reports.

Sana Biotechnology Stock Up 1.3%

Shares of SANA traded up $0.03 during trading hours on Friday, reaching $2.37. 2,288,443 shares of the stock traded hands, compared to its average volume of 2,997,985. Sana Biotechnology has a 52 week low of $2.22 and a 52 week high of $5.49. The stock has a fifty day simple moving average of $2.92 and a 200 day simple moving average of $3.36.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on SANA shares. Wall Street Zen downgraded Sana Biotechnology from a “hold” rating to a “sell” rating in a research note on Monday, July 20th. TD Cowen upgraded Sana Biotechnology to a “strong-buy” rating in a report on Monday, August 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sana Biotechnology in a research report on Wednesday, October 21st. Finally, Bank of America cut their target price on Sana Biotechnology from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $9.60.

About Sana Biotechnology

Sana Biotechnology, Inc is a clinical-stage biotechnology company focused on developing engineered cell and gene therapies for serious diseases. The company’s approach is designed to create durable treatments by modifying cells outside or inside the body and using them to replace, repair, or supplement damaged or missing biological functions.

Sana is developing proprietary technologies intended to support the delivery and persistence of therapeutic cells. These include platforms for engineering cells to evade immune-system detection, potentially allowing donor-derived cells to be used without extensive immune suppression, as well as methods for delivering genetic instructions directly to targeted tissues.